PDL BioPharma News
2 Biotechs to Avoid, 1 to Buy
PDL BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote ofMay 22
Theravance Looks to Reward Shareholders by Splitting Into Two Distinct Companies
The yields look great, but these 2 health-care dividend stocks could be the scariest ones around in the near future.
PDL BioPharma posted first-quarter 2013 earnings of 36 cents per share, below the Zacks Consensus Estimate of 38 cents.